DE ROOS, B., WOOD, S., BREMNER, D., BASHIR, S., BETANCOR, M.B., FRASER, W.D., DUTHIE, S.J., HORGAN, G.W. and SNEDDON, A.A. [2020]. The nutritional and cardiovascular health benefits of rapeseed oil-fed farmed salmon in humans are not decreased compared with those of traditionally farmed salmon: a randomized controlled trial. *European journal of nutrition* [online], Online First. Available from: https://doi.org/10.1007/s00394-020-02396-w

The nutritional and cardiovascular health benefits of rapeseed oil-fed farmed salmon in humans are not decreased compared with those of traditionally farmed salmon: a randomized controlled trial.

DE ROOS, B., WOOD, S., BREMNER, D., BASHIR, S., BETANCOR, M.B., FRASER, W.D., DUTHIE, S.J., HORGAN, G.W. and SNEDDON, A.A.

2020
The nutritional and cardiovascular health benefits of rapeseed oil-fed farmed salmon in humans are not decreased compared with those of traditionally farmed salmon: a randomized controlled trial

Baukje de Roos1 · Sharon Wood1 · David Bremner1 · Shabina Bashir1 · Monica B. Betancor2 · William D. Fraser3 · Susan J. Duthie1,4 · Graham W. Horgan5 · Alan A. Sneddon1

Received: 5 May 2020 / Accepted: 23 September 2020
© The Author(s) 2020

Abstract
Purpose Farmed fish are increasingly raised on feeds containing vegetable oils, which affects their composition and possibly health properties. We investigated the effects of consuming farmed salmon, raised on different feeding regimes, on nutrient status and health outcomes in healthy subjects.

Methods Salmon were grown on feeds containing mainly fish oil (FO) or rapeseed oil (RO), resulting in an eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) content of fillets of 2.1 or 0.9 g/100 g, respectively. In a randomized parallel controlled trial, 51 healthy subjects were allocated to consume 2 portions/week of FO salmon (n = 17), RO salmon (n = 17) or no additional salmon (Control, n = 17) as part of their habitual diet, for 18 weeks. We collected blood at 0, 9 and 18 weeks to measure omega-3 index (O3I) in red blood cells, plasma markers of cardiovascular risk, serum 25(OH)-vitamin D3 (25(OH)D3) and plasma trace elements.

Results After 18 weeks, O3I was similarly increased in subjects consuming 2 portions/week of FO or RO salmon compared to control (both p < 0.05). Serum 25(OH)D3 was significantly higher, whereas plasma triacylglycerols were significantly lower in subjects consuming RO salmon compared to control (both p < 0.05). Heart rate was significantly lower in subjects consuming FO salmon after 9 weeks, compared to control (p < 0.01). Salmon consumption did not affect other markers.

Conclusion Consuming two portions/week of salmon raised on rapeseed oil rather than fish oil increased the O3I and vitamin D status, and decreased plasma triacylglycerols. These outcomes endorse opportunities for developing more sustainable feeds within aquaculture food systems.

Clinical trial registry This trial was registered at clinicaltrials.gov as NCT01916434.

Keywords Farmed fish · Fish feeds · Cardiovascular health · Omega-3 index · Vitamin D · Micronutrients

Abbreviations
25(OH)D3 25(OH)-vitamin D3
CVD Cardiovascular disease
FO salmon Salmon fed a fish oil-rich diet
hs-CRP High-sensitivity C-reactive protein
ICP-MS Inductively coupled plasma mass spectrometry
n-3 LCPUFA N-3 long-chain polyunsaturated fatty acids
NEFA Non-esterified fatty acids
O3I Omega-3-index
RCT Randomized controlled trial
RO salmon Salmon fed a rapeseed oil-rich diet
s-ICAM Soluble ICAM
sP-selectin Soluble P-selectin
Introduction

Worldwide, fish is a valuable dietary source of not only energy, protein and n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA), but also vitamins such as A and D, and micronutrients such as selenium, zinc and magnesium [1]. Whilst the health benefits of seafood consumption have traditionally been attributed to its content of n-3 LCPUFA [1], a recent systematic assessment of the effects of n-3 LCPUFA supplements concluded that increasing their consumption had little or no effect on mortality or cardiovascular health [2]. Nevertheless, two meta-analyses of fish intervention studies confirmed that, compared with very low fish intake (i.e., < 1 serving/month), low or moderate fish intake (i.e., 1 or 2 servings/week) significantly reduced the risk for coronary heart disease and stroke [3, 4]. Furthermore, meta-analysis of observational data indicated a moderate and inverse association between fish consumption and cerebrovascular risk, whilst this was not the case for n-3 LCPUFA status in observational studies, or supplement intake in primary and secondary prevention trials [5]. This suggests that the beneficial effect of fish intake on disease risk could be mediated through an interplay of different nutrients in fish.

The total supply of fish for food consumption has increased significantly in the past five decades due to population growth, rising incomes, urbanization and a strong expansion of global production and distribution networks. Further growth in fish consumption levels will be increasingly dependent on aquaculture. Indeed, aquaculture already makes a crucial contribution to local diets and economies in many countries [6, 7]. Expanding the aquaculture sector has the potential to reduce the burden on wild fish stocks whilst meeting the dietary needs of the population for n-3 LCPUFA and other nutrients [8]. However, there is a strong need to understand the effect of pressures from sustainability on methods of production and the health-giving properties of fish. In the past decades, the aquaculture industry has improved the sustainability of fish production by lowering the input–output ratios for salmon [9]. Traditional fish oil in formulated fish diets is increasingly being replaced by oil from plant-based sources. Among such oils, rapeseed oil is the most frequently utilized fish oil alternative in European aquaculture systems, mainly due to its ready availability and favorable price [10]. However, use of a terrestrial oil such as rapeseed may lower concentrations of the main n-3 LCPUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as other important nutrients in fish, and thereby the subsequent health benefits to the consumer [11]. Consequently, the objective of this study was to: (i) assess the effects of consuming two portions per week of farmed salmon reared on different feeding regimes on the omega-3 index (primary outcome), micronutrient concentrations and cardiovascular health outcomes, (secondary outcomes) in healthy subjects and (ii) evaluate how changes in health outcomes may be related to compositional differences of the salmon.

Subjects and methods

Growing of salmon

Atlantic salmon (Salmo salar L.) were grown by Marine Harvest (now MOWI) at Ardnish fish farm in Lochailort, United Kingdom, between April 2012 and January 2013 on fish feed that was produced to differ in n-3 LCPUFA (BioMar Ltd). One group of salmon received traditional high fish meal and high fish oil feed with high concentrations of EPA and DHA (FO group: EPA + DHA ~15% of total feed fatty acids); whereas, the other group of salmon were fed diets where the majority of the fish oil was replaced by vegetable oils (mainly rapeseed oil) with lower concentrations of EPA and DHA (RO group: EPA + DHA ~6–8% of total feed fatty acids). The composition of the fish diets and feeding schedule is outlined in Supplementary Tables 1a and 1b. After 9 months, salmon length and weight were similar between both groups (Supplementary Table 2). Fish were harvested, gutted and filleted, and two portions were cut from the center part of each salmon. The average portion size was 157.1 g (SD 43.5 g, n = 300) for RO salmon and 153.9 g (SD 33.6 g, n = 300) for RO salmon. Fillets were vacuum packed, snap frozen and stored at − 80 °C for the duration of the human intervention study. Storage of salmon at − 80 °C for 12 months did not affect the fatty acid composition of the salmon (Supplementary Fig. 1).

Compositional analysis of salmon fillets

Routine proximate analytical procedures were used to establish the macronutrient composition of the salmon. Total fat was determined by the Soxtec method (Soxtec 2050 Auto Fat Extraction System) [12]. Protein was measured as total nitrogen by the Dumas combustion method using a Vario Max CN analyzer. The nitrogen content was multiplied by 6.25 to calculate the protein concentration [13]. For fatty acid analysis, total lipids from diet subsamples were extracted using the method of Folch [14], and total lipid was then converted to its methyl esters by direct trans-esterification using 1% sulphuric acid in methanol. The proportion of individual fatty acids in the diet was determined with an Agilent 6890 gas chromatograph fitted with a 30 m DB23 capillary column (J&W Scientific, Folsom, CA, USA) as described by us previously [15]. Trace element concentrations were
determined after digestion in nitric acid using the MARS 6 digestion system (CEM Corp., Matthews, NC, USA) by inductively coupled mass spectrometry (ICP-MS) analysis as previously described [16]. The accuracy of methods was assessed using certified reference materials (skimmed milk powder, LGC Group, Middlesex, UK, and whole blood, SERO AS, Billingstad, Norway). The composition of the salmon fillets is indicated in Table 1.

**Human intervention study**

**Ethics**

The study was carried out in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice. The study was approved by the Ethics Committee of the Rowett Institute, University of Aberdeen.

**Study subjects and study design**

This was a randomized parallel intervention study in healthy and free-living male and female subjects. All subjects provided informed consent and completed a health questionnaire prior to starting the study. Eligibility was established through a health questionnaire and a screening blood sample. Inclusion criteria were men and women aged 35–75 years; BMI ranging from 25–35 kg/m²; normal results on full blood count (haematocrit above 40% for males and above 35% for females; hemoglobin above 13 g/dL for males and above 11.5 g/dL for females); blood pressure below 160/90 mmHg; fasting plasma glucose < 7 mmol/L; normal results of fasting plasma lipids (total cholesterol < 8 mmol/L, total/HDL cholesterol < 6 mmol/L). Exclusion criteria were regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs; taking drugs or herbal medicines known to alter the haemostatic system in general; taking any medicine known to affect lipid metabolism; taking dietary supplements/multivitamin tablets; diagnosis of diabetes, hypertension, renal, hepatic, hematological disease or coronary heart disease; having given a pint of blood for transfusion purposes within the last month; unsuitable veins for blood sampling; inability to understand the participant information sheet; inability to speak, read and understand the English language.

**Study protocol**

Eligible subjects were randomized to 1 of the 3 possible parallel interventions, matched for gender, age and BMI, by an independent statistician, based on the employment of covariate balancing/minimization. Subjects were then asked to either consume (i) 2 portions of FO salmon per week on top of habitual fish consumption, (ii) 2 portions of RO salmon per week on top of habitual fish consumption, or (iii) continue with habitual fish consumption (Control), for 18 weeks. Either FO or RO salmon portions were provided to the subjects in each group at the start of the study and at their 9-week study visit. The primary outcome in this study was the O3I. A daily intake of ~0.5 g n-3 LCPUFA was expected to increase the O3I from ~4% to ~6% after 18 weeks, and a daily intake of ~1 g n-3 LCPUFA would be expected to produce twice this increase [17, 18]. Five previous human

| Table 1 | Levels of nutrients in salmon fillets used for the intervention |
|---------|---------------------------------------------------------------|
|         | FO salmon (g/100 g wet weight fillet) | RO salmon (g/100 g wet weight fillet) | p value |
| Protein | 19.4 ± 0.8 | 19.1 ± 0.5 | 0.39 |
| Total N | 3.1 ± 0.1 | 3.1 ± 0.1 | 0.39 |
| Carbohydrates | 0.2 ± 0.0 | 0.1 ± 0.0 | 0.02 |
| Fat, total | 10.8 ± 2.1 | 10.8 ± 1.5 | 0.98 |
| Saturated fat | 3.0 ± 0.6 | 2.3 ± 0.3 | 0.04 |
| Monounsaturated fat | 3.7 ± 0.7 | 4.7 ± 0.6 | 0.06 |
| Polyunsaturated fat | 4.1 ± 0.8 | 3.8 ± 0.5 | 0.56 |
| n-6 PUFA | 1.5 ± 0.1 | 2.1 ± 0.1 | 0.00 |
| n-3 PUFA | 2.6 ± 0.1 | 1.7 ± 0.1 | 0.00 |
| EPA + DHA (% of total fat) | 2.1 ± 0.4 (19.5%) | 0.9 ± 0.1 (8.8%) | 0.00 |
| Moisture | 63.4 ± 2.0 | 65.3 ± 3.1 | 0.30 |
| Ash | 2.2 ± 0.2 | 2.0 ± 0.2 | 0.19 |
| Vitamin D3 (µg/100 g) | 1.8 ± 0.1 | 1.4 ± 0.1 | 0.00 |
| Selenium (µg/100 g) | 17.8 ± 2.2 | 19.3 ± 4.5 | 0.30 |
| Zinc (µg/100 g) | 578.3 ± 108.9 | 622.4 ± 23.5 | 0.16 |
| Magnesium (mg/100 g) | 28.6 ± 3.2 | 26.3 ± 1.9 | 0.60 |

Values are means ± SEMs (n = 5 fillets)
intervention studies with n-3 LCPUFA showed an average SD index% between 0.78 and 0.92%, with a mean SD of change of 0.85% (data supplied by W. Harris). To detect a group difference of 1% for this SD, on the basis of a 5% significance level and a power of 90% for detecting a main effect on the omega-3 index, a sample size of 17 per each intervention and control group would be required.

Subjects attended the Human Nutrition Unit at the Rowett Institute in Aberdeen, United Kingdom, after an overnight fast of ≥ 10 h, just before the start of the study, and after 9 and 18 weeks of intervention, where their blood pressure and heart rate were measured, and a blood sample was taken. Prior to the visits at the start and during the 18th week of intervention, 4-day estimated food diaries were recorded by each participant. Blood samples (70 mL) were obtained using siliconized 21-gauge butterfly needles into vacutainer serum tubes containing either EDTA as anticoagulant or vacutainer serum tubes (Becton Dickinson, Oxford, UK). Whole blood samples were used for blood cell count using a Sysmex KX21 (Sysmex Ltd, UK). 100 µL of whole blood was frozen at − 70 °C for the analysis of fatty acid composition in red blood cells (RBC). Plasma was obtained by centrifuging whole blood at 2000g for 15 min and stored at − 70 °C for the analysis of markers of lipid metabolism, glucose, insulin, inflammation and elements. Serum samples were collected after whole blood was left to clot for 1 h and then centrifuged for 2000g for 15 min. The serum was stored at − 70 °C for the analysis of 25(OH)D3.

Compliance was calculated at the end of the study from participant’s diaries and fish logs with the following formula: compliance (%) = number of salmon portions eaten over 18 weeks/36 (number that should have been eaten over 18 weeks). The 4-day food diaries were analyzed with the NetWISP analysis program (version 3.0) (Tinuviel Software, Llanfechell, Anglesey, UK) using the UK Nutrient Databank [19].

Biochemical analyses

Fatty acid composition in red blood cells

Fatty acid composition in red blood cells (RBC) was performed as described by Harris et al. [18], using an Agilent 6890 gas chromatograph as described above [15]. The O3I was subsequently calculated as the absolute amount of EPA + DHA as percentage of total fatty acids [17].

Analysis of cardiovascular risk markers

Glucose, total cholesterol, HDL cholesterol, triacylglycerols and non-esterified fatty acids (NEFAs) were measured in plasma on an automated clinical analyzer (KONELAB30, Thermo Fisher Scientific, UK) using kits obtained from Microgenics GmbH, UK. LDL cholesterol was calculated with the Friedewald formula [20]. Clottable fibrinogen was measured in plasma in duplicate according to the method [21] in a semi-automated coagulometer (Schnittger and Gross, Burkard Scientific (Sales) Ltd., UK). Soluble intercellular adhesion molecule-1 (sICAM-1), soluble P-selectin (sP-selectin) and high-sensitivity C-reactive protein (hs-CRP) were analyzed in plasma with Platinum ELISA kits (Bender MedSystems GmbH, Austria); insulin was analyzed in plasma with a Mercodia ELISA kit (Mercodia, Uppsala, Sweden). All samples were measured in duplicate.

Vitamin D analysis

The vitamin D metabolite 25(OH)D3 was analyzed in serum as described [22]. This LC–MS/MS method has previously been validated against other commercially available assays and is regarded as the most valid and reliable technique for the assessment of vitamin D metabolites including 25(OH)D3 [23]. All samples were measured once, with a subset of 9 samples measured in duplicate.

Trace element analysis

Plasma concentrations of selenium, zinc and magnesium were analyzed by diluting plasma into concentrated nitric acid (65% (v/v)) and then incubating at 165 °C for 10 min followed by analysis using ICP-MS as previously described [16]. The accuracy of the method was assessed using certified reference materials: whole blood (Seronorm Whole Blood L-3) and serum (Seronorm Serum L-1) (SERO AS, Billingstad, Norway). The median recovery values of the relevant elements were within the certified ranges indicated by the supplier. All samples were measured in duplicate.

Statistical analysis

Statistical analysis was carried out using R 3.4.0 (R Foundation for Statistical Computing, Vienna). Baseline data were analyzed by Analysis of Variance with terms for participant age, gender, BMI and treatment group. Outcome data were analyzed by Analysis of Variance with terms for participant age, gender, BMI, baseline value and treatment group. The treatment term was also split into contrasts between the control and intervention diet. We also examined analyses including interactions between treatment group and participant age and gender, but these were not significant. Models with a time of year effect were also examined, and although these effects were significant for some outcomes, they did not affect the conclusions about treatment effects. Differences between treatment groups were tested by post hoc tests with Tukey adjustment for multiple comparisons. Results at 9 and
18 weeks are presented as separate analysis, as a repeated measures analysis did not add any additional information.

**Results**

**Salmon composition**

FO salmon contained 10.8 g/100 g fat of which 10.5% was EPA and 9% DHA (Table 1). Thus, two 157.1 g portions/week of FO salmon provided ~6.6 g of EPA + DHA per week (or ~0.9 g/day). RO salmon also contained 10.8 g/100 g fat of which 4.2% was EPA and 4.6% was DHA (Table 1). Thus, two 153.9 g portions of RO salmon provided ~2.8 g of EPA + DHA per week (or ~0.4 g/day). Consumption of two portions/week of either the FO or RO salmon provided ~4–5% of the RDA for vitamin D, ~15% of the RDA for selenium, and ~3–6% of the RDA for zinc and magnesium (Table 1). FO salmon contained significantly higher amounts of carbohydrates, saturated fat, n-3 LCPUFA, EPA + DHA and vitamin D₃, and significantly lower amounts of n-6 PUFA, compared with RO salmon (Table 1).

**Recruitment of subjects**

A total of 75 subjects were recruited between November 2012 and August 2013. Of these subjects, 11 did not meet the inclusion criteria and 11 declined to participate. 53 subjects were allocated to the three intervention groups, but one participant withdrew because of fainting during blood sampling, and one participant because of an unrelated medical intervention. Therefore, 51 subjects completed the intervention with 17 subjects in each of the three intervention groups (Fig. 1). The study ended in January 2014. Baseline characteristics of the subjects did not significantly differ between these three groups (Table 2).

**Fig. 1** Flow chart of participant recruitment

| Assessed for eligibility (n=75) | Excluded (n=22) |
|--------------------------------|-----------------|
| • Not meeting inclusion criteria (n=11) |
| • Declined to participate (n=11) |

| Randomized (n=53) |
|-------------------|
| Allocated to FO salmon group (n=19) |
| Discontinued intervention (n=2) |
| (Fainted after baseline sample (n=1) |
| Started medical treatment (n=1)) |
| Analysed (n=17) |

| Allocated to RO salmon group (n=17) |
| Analysed (n=17) |

| Allocated to Control group (n=17) |
| Analysed (n=17) |

**Table 2** Characteristics of subjects at baseline

|                      | FO salmon (n = 17) | RO salmon (n = 17) | Control (n = 17) |
|----------------------|--------------------|--------------------|-----------------|
| Age (years)          | 55 ± 3             | 53 ± 3             | 54 ± 3          |
| Sex (female/male)    | 10/7               | 10/7               | 11/6            |
| BMI (kg/m²)          | 25.9 ± 1.0         | 25.5 ± 0.9         | 26.5 ± 1.0      |
| Systolic blood pressure (mm Hg) | 131.2 ± 4.2     | 129.2 ± 3.5       | 133.4 ± 3.0    |
| Diastolic blood pressure (mm Hg) | 80.7 ± 2.3        | 79.8 ± 1.7        | 78.1 ± 2.6     |
| Heart rate (beats/min) | 64.3 ± 2.3        | 64.3 ± 2.0        | 63.1 ± 3.1     |

Values are means ± SEMs (all such values)
Effect of intervention on dietary intake, compliance to fish intervention and body weight

Compliance for the salmon intervention was 83% for 1 participant in the RO salmon group and 100% for the other 33 subjects. Analysis of the food diaries from the subjects from the FO salmon, RO salmon and control groups showed that there were no significant changes in habitual fish intake across the study period (data not shown). Mean intake of energy and macronutrients from the diets at baseline and after 18 weeks of intervention was not different between groups, apart from salt intake at 18 weeks, which was significantly higher in the control group than in the FO and RO salmon groups (p < 0.05) (Table 3). Mean body weight did not change during the intervention period in the FO salmon, RO salmon and control groups (data not shown).

Table 3  Mean daily intake of energy, macronutrients, salt, fibre and alcohol in subjects at baseline and after 18 weeks of intervention

|                     | FO salmon (n = 15) | RO salmon (n = 17) | Control (n = 15) | P_{treatment} |
|---------------------|--------------------|--------------------|-----------------|--------------|
| **Energy (kcal)**   |                    |                    |                 |              |
| Baseline            | 1897 ± 133         | 1775 ± 114         | 1898 ± 115      | 0.29         |
| 18 weeks            | 1844 ± 154         | 1822 ± 101         | 1912 ± 114      | 0.72         |
| **Protein (g)**     |                    |                    |                 |              |
| Baseline            | 82.0 ± 5.0         | 70.4 ± 4.2         | 79.4 ± 5.7      | 0.43         |
| 18 weeks            | 74.9 ± 5.5         | 71.5 ± 3.2         | 80.3 ± 4.6      | 0.18         |
| **Carbohydrates (g)** |                  |                    |                 |              |
| Baseline            | 227.8 ± 19.3       | 212.4 ± 14.4       | 208.6 ± 16.0    | 0.57         |
| 18 weeks            | 210.9 ± 22.6       | 218.8 ± 13.5       | 204.9 ± 14.9    | 0.40         |
| **Total fat (g)**   |                    |                    |                 |              |
| Baseline            | 76.4 ± 5.7         | 69.0 ± 5.3         | 80.1 ± 6.5      | 0.19         |
| 18 weeks            | 76.8 ± 6.0         | 71.4 ± 4.8         | 83.1 ± 5.5      | 0.55         |
| **Saturated fat (g)** |                  |                    |                 |              |
| Baseline            | 27.4 ± 2.6         | 26.2 ± 2.4         | 30.6 ± 3.2      | 0.29         |
| 18 weeks            | 27.0 ± 2.5         | 25.7 ± 1.9         | 32.0 ± 3.3      | 0.33         |
| **Polyunsaturated fat (g)** |          |                    |                 |              |
| Baseline            | 12.7 ± 1.0         | 10.9 ± 1.0         | 12.0 ± 1.4      | 0.49         |
| 18 weeks            | 12.9 ± 1.2         | 12.7 ± 1.3         | 13.2 ± 1.2      | 0.88         |
| **Monounsaturated fat (g)** |           |                    |                 |              |
| Baseline            | 22.4 ± 1.8         | 20.7 ± 1.6         | 25.1 ± 2.8      | 0.22         |
| 18 weeks            | 21.4 ± 2.1         | 21.3 ± 1.6         | 25.2 ± 1.9      | 0.49         |
| **Salt (g)**        |                    |                    |                 |              |
| Baseline            | 6.1 ± 0.5          | 6.5 ± 0.7          | 6.3 ± 0.6       | 0.89         |
| 18 weeks            | 5.8 ± 0.6          | 5.7 ± 0.4          | 7.2 ± 0.6       | 0.03         |
| **Fiber (g)**       |                    |                    |                 |              |
| Baseline            | 21.8 ± 2.0         | 18.7 ± 1.2         | 18.9 ± 1.5      | 0.27         |
| 18 weeks            | 22.0 ± 2.4         | 19.9 ± 1.5         | 20.9 ± 1.9      | 0.68         |
| **Alcohol (g)**     |                    |                    |                 |              |
| Baseline            | 4.6 ± 1.7          | 11.0 ± 2.9         | 11.6 ± 3.0      | 0.08         |
| 18 weeks            | 9.3 ± 3.9          | 10.3 ± 2.6         | 11.5 ± 3.0      | 0.84         |

*All values are means ± SEMs. Only subjects providing both food diaries (week 0 and week 18) were included in the analysis (n = 15, 17 and 15 in the FO salmon, RO salmon and Control group, respectively). P_{treatment} = p value for treatment effect between groups.
after 18 weeks of intervention (p<0.01), compared with the control group, Plasma triacylglycerols were significantly lower in subjects consuming RO salmon, compared with RO salmon, led to a preferential incorporation of EPA into RBC membranes (Fig. 2c, d). Predicted O3I (%), and arachidonic acid, and consumption of FO salmon, compared with RO salmon (gray) and control (white) groups; p<0.01 for differences from control group; p<0.05 for difference between FO and RO salmon groups. b: Correlation of changes in O3I with the intake of EPA + DHA per kg of body weight across the FO salmon (black), RO salmon (gray) and control (white) groups after 18 weeks of intervention. Changes in the abundance of individual fatty acids in RBC upon consumption of c: FO (black) or d: RO (gray) salmon for 18 weeks. p<0.05 for differences from control group; *p<0.05 for differences between FO and RO salmon groups.

into RBC occurred mostly at the expense of linoleic acid and arachidonic acid, and consumption of FO salmon, compared with RO salmon, led to a preferential incorporation of EPA into RBC membranes (Fig. 2c, d). Predicted O3I (%), calculated with an algorithm based on studies with fish oil supplements [24], using a dose of EPA + DHA of 900 mg/day for the FO group and 400 mg/day for the RO group (see above) showed a good alignment with observed O3I values for all three intervention groups (Fig. 3).

**Effect of intervention on cardiovascular risk markers**

Plasma triacylglycerols were significantly lower in subjects consuming RO salmon, compared with the control group, after 18 weeks of intervention (p<0.05) (Table 4). None of the other plasma lipids were significantly affected by the salmon intervention. Heart rate was significantly lower in subjects consuming FO salmon, compared with control, but only after 9 weeks of intervention (p<0.01) (Table 4). Blood pressure and metabolic markers were not affected by the salmon intervention, although revised QUICKI, a marker of insulin sensitivity, was slightly but significantly lower in the FO group compared with the control group (p<0.05) (Table 4). Unexpectedly, baseline plasma concentrations of EPA + DHA at baseline were significantly lower in the salmon intervention groups compared with the control group (light gray) and white circles the Control group. The solid line represents the line y=x, illustrating the 'perfect prediction'. The dashed lines represent the best fit lines of the predicted compared with observed O3I values for the FO salmon group (black), the RO salmon group (dark gray) and the control group (light gray).

**Fig. 2** Changes in RBC fatty acid composition upon consumption of 2 portions of FO or RO salmon per week or no additional salmon (control), after 9 and 18 weeks. Data are means ± SEM. a: Change in O3I from baseline at 9 weeks and 18 weeks for FO salmon (black), RO salmon (gray), control (white) groups; *p<0.01 for differences from control group; #p<0.05 for differences from control group; *p<0.05 for difference between FO and RO salmon groups. b: Correlation of changes in O3I with the intake of EPA + DHA per kg BW/wk.

**Fig. 3** Predicted versus actual O3I (%). The predicted O3I=baseline O3I – the predicted change in O3I, with the latter being calculated with an algorithm based on studies with fish oil supplements (21): 2.60+0.921 × 1 – 0.842 × baseline O3I + 0.05 × (baseline O3I)² + 0.0027 × [dose EPA + DHA in mg/day] – 0.000000471 × [dose EPA + DHA in mg/day]². The dose of EPA + DHA/day used was 900 mg/day for the FO salmon group and 400 mg/day for the RO salmon group (see “Results”). Black circles represent the FO salmon group, gray circles the RO salmon group, and white circles the Control group. The solid line represents the line y=x, illustrating the ‘perfect prediction’. The dashed lines represent the best fit lines of the predicted compared with observed O3I values for the FO salmon group (black), the RO salmon group (dark gray) and the control group (light gray).
|                                | FO salmon (n = 17) | RO salmon (n = 17) | Control (n = 17) | \( p_{\text{treatment}} \) |
|--------------------------------|---------------------|--------------------|-----------------|--------------------------|
| **Systolic blood pressure (mm Hg)** |                     |                    |                 |                         |
| Baseline                        | 131.2 ± 4.2         | 129.2 ± 3.5        | 133.4 ± 3.0     | 0.896                   |
| 9 weeks                         | 130.3 ± 3.5         | 125.4 ± 2.8        | 131.5 ± 3.1     | 0.296                   |
| 18 weeks                        | 129.3 ± 3.5         | 120.8 ± 3.1        | 129.5 ± 3.9     | 0.136                   |
| **Diastolic blood pressure (mm Hg)** |                     |                    |                 |                         |
| Baseline                        | 80.7 ± 2.3          | 79.8 ± 1.7         | 78.1 ± 2.6      | 0.427                   |
| 9 weeks                         | 80.0 ± 1.9          | 80.2 ± 1.8         | 81.4 ± 2.1      | 0.275                   |
| 18 weeks                        | 77.9 ± 2.0          | 75.4 ± 2.1         | 77.8 ± 2.4      | 0.374                   |
| **Heart rate (beats/min)**      |                     |                    |                 |                         |
| Baseline                        | 64.4 ± 2.3          | 64.3 ± 2.0         | 63.2 ± 3.1      | 0.592                   |
| 9 weeks                         | 58.4 ± 2.2          | 63.9 ± 2.4         | 65.4 ± 3.3      | 0.002                   |
| 18 weeks                        | 61.9 ± 2.0          | 64.9 ± 2.8         | 65.0 ± 3.3      | 0.571                   |
| **Total cholesterol (mmol/L)**  |                     |                    |                 |                         |
| Baseline                        | 5.42 ± 0.30         | 5.49 ± 0.22        | 5.41 ± 0.28     | 0.864                   |
| 9 weeks                         | 5.66 ± 0.33         | 5.70 ± 0.22        | 5.54 ± 0.27     | 0.889                   |
| 18 weeks                        | 5.71 ± 0.28         | 5.46 ± 0.17        | 5.60 ± 0.27     | 0.123                   |
| **HDL cholesterol (mmol/L)**    |                     |                    |                 |                         |
| Baseline                        | 1.52 ± 0.08         | 1.74 ± 0.14        | 1.66 ± 0.11     | 0.251                   |
| 9 weeks                         | 1.68 ± 0.10         | 1.78 ± 0.13        | 1.74 ± 0.12     | 0.193                   |
| 18 weeks                        | 1.71 ± 0.11         | 1.73 ± 0.15        | 1.75 ± 0.11     | 0.012                   |
| **LDL cholesterol (mmol/L)**    |                     |                    |                 |                         |
| Baseline                        | 3.53 ± 0.26         | 3.33 ± 0.20        | 3.35 ± 0.22     | 0.781                   |
| 9 weeks                         | 3.53 ± 0.31         | 3.53 ± 0.24        | 3.43 ± 0.19     | 0.508                   |
| 18 weeks                        | 3.52 ± 0.24         | 3.29 ± 0.20        | 3.44 ± 0.21     | 0.393                   |
| **Triglycerides (mmol/L)**      |                     |                    |                 |                         |
| Baseline                        | 1.35 ± 0.18         | 1.26 ± 0.13        | 1.19 ± 0.12     | 0.660                   |
| 9 weeks                         | 1.19 ± 0.15         | 1.17 ± 0.11        | 1.19 ± 0.15     | 0.533                   |
| 18 weeks                        | 1.24 ± 0.21         | 1.08 ± 0.12        | 1.31 ± 0.16     | 0.050                   |
| **Glucose (mmol/L)**            |                     |                    |                 |                         |
| Baseline                        | 5.53 ± 0.12         | 5.67 ± 0.15        | 5.57 ± 0.12     | 0.599                   |
| 9 weeks                         | 5.73 ± 0.13         | 5.71 ± 0.22        | 5.62 ± 0.11     | 0.711                   |
| 18 weeks                        | 5.62 ± 0.10         | 5.65 ± 0.18        | 5.66 ± 0.11     | 0.804                   |
| **Insulin (mU/L)**              |                     |                    |                 |                         |
| Baseline                        | 7.71 ± 1.83         | 6.56 ± 0.95        | 6.13 ± 0.53     | 0.579                   |
| 9 weeks                         | 6.52 ± 0.68         | 6.45 ± 0.88        | 6.10 ± 0.64     | 0.717                   |
| 18 weeks                        | 6.86 ± 0.95         | 6.56 ± 0.80        | 6.37 ± 0.72     | 0.845                   |
| **NEFA (mmol/L)**               |                     |                    |                 |                         |
| Baseline                        | 0.44 ± 0.04         | 0.44 ± 0.05        | 0.53 ± 0.05     | 0.270                   |
| 9 weeks                         | 0.44 ± 0.05         | 0.45 ± 0.05        | 0.47 ± 0.06     | 0.455                   |
| 18 weeks                        | 0.54 ± 0.05         | 0.43 ± 0.03        | 0.45 ± 0.04     | 0.055                   |
| **HOMA-IR**                     |                     |                    |                 |                         |
| Baseline                        | 1.95 ± 0.50         | 1.63 ± 0.21        | 1.53 ± 0.14     | 0.593                   |
| 9 weeks                         | 1.66 ± 0.17         | 1.65 ± 0.22        | 1.53 ± 0.17     | 0.638                   |
| 18 weeks                        | 1.66 ± 0.26         | 1.63 ± 0.19        | 1.62 ± 0.19     | 0.725                   |
| **revQUICKI**                   |                     |                    |                 |                         |
| Baseline                        | 0.427 ± 0.016       | 0.421 ± 0.009      | 0.414 ± 0.010   | 0.684                   |
| 9 weeks                         | 0.430 ± 0.014       | 0.424 ± 0.011      | 0.437 ± 0.019   | 0.226                   |
| 18 weeks                        | 0.404 ± 0.010       | 0.421 ± 0.007      | 0.424 ± 0.011   | 0.041                   |
| **Fibrinogen (g/L)**            |                     |                    |                 |                         |
| Baseline                        | 2.86 ± 0.07         | 2.62 ± 0.05        | 2.60 ± 0.10     | 0.006                   |
| 9 weeks                         | 2.74 ± 0.09         | 2.72 ± 0.08        | 2.66 ± 0.11     | 0.267                   |
the inflammatory markers, fibrinogen, hs-CRP and s-ICAM were significantly higher in the FO and RO groups, compared with the control group. However, inspection of relationships between baseline inflammatory markers and responses in O3I and plasma triacylglycerols did not reveal a consistent relationship between both (Supplementary Fig. 2).

**Effect of intervention on serum 25(OH)D3, and plasma concentrations of trace elements**

Serum 25(OH)D3 was significantly higher in subjects consuming RO salmon compared with the control group after 18 weeks of intervention (p < 0.05) (Table 5). Changes in serum 25(OH)D3 were also significantly correlated with changes in the O3I across all subjects (r = 0.33, p = 0.02). Plasma concentrations of selenium, zinc and magnesium were not affected after 18 weeks of intervention (Table 5).

**Discussion**

In this study, consumption of 2 portions of farmed salmon per week, raised on fish oil or rapeseed oil-based feeds, increased the O3I to a similar extent after 18 weeks.
Consumption of salmon raised on fish oil-based feed significantly decreased heart rate, but only after 9 weeks, and consumption of salmon raised on rapeseed oil-based feed significantly increased serum levels of 25(OH)D3 and decreased plasma triacylglycerols after 18 weeks of intervention. Thus, the nutritional and cardiovascular health benefits of rapeseed oil-fed farmed salmon in humans were not less significant than those of traditionally farmed salmon, despite containing only half the amounts of EPA and DHA.

Two other studies assessed the cardiovascular health benefits of consuming differently fed farmed fish. Consumption of Atlantic salmon grown on a 100% fish oil, but not on rapeseed oil, significantly increased serum n-3 PUFA concentrations and decreased serum triacylglycerols in coronary heart disease patients after 6 weeks [25]. Consumption of farmed trout raised on a marine but not plant-based feed significantly increased the O3I in healthy men after 8 weeks [26]. However, the duration of both studies may have been too short to reveal the cardiovascular health benefits of consuming fish raised on plant-based feeds. Whilst it takes days-to-weeks for maximal fatty acid incorporation into transport pools including serum/plasma, this can take weeks-to-months for functional pools like RBC [27], and this likely affects the time scale on which beneficial changes to cardiovascular health outcomes occur. In our study, the effects on the O3I and plasma triacylglycerols were more pronounced after 18 compared with 9 weeks of intervention, especially in the RO salmon group. After 18 weeks, the difference in O3I between the FO and RO salmon groups was no longer significant, although the RBC pool may not be as useful as plasma phosphatidyl choline and platelet pools for discriminating between different doses of n-3 LCPUFA [27].

The efficacy of farmed salmon or omega-3 supplements to increase the O3I appear similar (Fig. 3), indicating that changes in the O3I can be explained by intake of EPA and DHA, and that the bioavailability of n-3 LCPUFA from fish and supplements are comparable. The health implications of eating two oily fish per week are potentially significant, as previous studies have demonstrated that an O3I of ≥ 8% is associated with a lower risk of death from cardiovascular disease [28] and death from all causes [29]. Consumption of two portions/week of RO salmon also beneficially lowered plasma triacylglycerols. Other studies have found similar effects on serum/plasma triacylglycerols after shorter intervention periods, indicating that such effects are established within a couple of weeks, but mostly with relatively high intakes of fish (> 500 g/week). A 4-week intervention with 750 g/week of fatty fish in healthy subjects decreased serum triacylglycerols compared with lean meat [30]. Similarly, a 4-week lean-seafood intervention, supplied as 60% of total dietary protein, decreased fasting and postprandial serum triacylglycerols compared with a non-seafood intervention as part of a controlled diet in healthy subjects, despite the fact that both diets contained similar amounts of n-3 LCPUFA. Lowered serum triacylglycerol concentrations were associated with decreased fasting triacylglycerols in chylomicrons and VLDL, reduced fasting VLDL particle size and a reduced postprandial concentration of medium-sized VLDL particles [31]. In our study, we also found that consumption of FO salmon significantly decreased heart rate, but only after 9 weeks of intervention. Two meta-analyses of RCTs found that consumption of fish oil supplements reduced heart rate [32, 33], an effect that appeared to be predominantly attributable to DHA [32]. Interestingly, fish oil reduced heart rate particularly in those with higher baseline heart rate and those on longer treatment duration [33]; whereas, our findings provide evidence for a temporary decrease in heart rate. This may indicate that consumption of fish oil supplements rather than fish is more effective in modulating heart rate, and therefore risk of cardiovascular mortality, in the long term.

Fish, especially oily fish such as salmon, is also a major dietary source of vitamin D [34] and in our study, serum 25(OH)D3 concentrations were significantly correlated with the O3I. A recent meta-analysis found that consumption of at least two fish meals over 4 weeks was associated with a significant increase in 25(OH)D concentrations of ~4.4 nmol/L, albeit that consumption of fatty fish, longer study durations and lower baseline 25(OH)D concentrations were associated with larger increases in 25(OH)D concentrations [35]. However, increased consumption of (mostly farmed) fish did not affect plasma 25(OH)D concentrations despite increased vitamin D intake in another study [36]. In our study, which was not controlled for time of year and, thus, exposure to sunlight, subjects who consumed the RO salmon significantly improved their vitamin D status compared with subjects in the control group. However, FO and RO salmon provided approximately 0.8 and 0.6 µg/day of vitamin D3, respectively, which is well below the recommended 10 µg/day in the UK, or 10–20 µg/day in the USA. Therefore, increasing consumption of farmed salmon alone may not be sufficient to optimize vitamin D status [35]. Furthermore, vitamin D3 levels in aquaculture feeds have fallen in the past decades [37], as fish feeds with terrestrial components are generally devoid of this vitamin, with levels in farmed salmon being 25% lower than in wild salmon [34]. Therefore, this study highlights the importance of optimizing levels of vitamin D and other micronutrients in fish feeds to enhance the nutritional value of farmed fish to consumers in the future.

A growing number of studies have highlighted the contribution of fish consumption to adequate intake of micronutrients on a global scale [38, 39], although the actual contribution of fish to individual micronutrient status is debated. Despite increased total fish consumption...
in Bangladesh in the past two decades, mostly through increased consumption of farmed fish, iron and calcium intake from fish have decreased, whilst no significant changes in intakes of zinc, vitamin A and vitamin B12 have occurred, possibly reflecting lower overall nutritional quality of farmed fish [40]. Indeed, selenium levels in farmed salmon raised on increased levels of terrestrial-based diets have been shown to decrease by 50% [41]. In our study, we found no effect of salmon consumption on plasma concentrations of selenium, zinc or magnesium, which is perhaps expected considering the relatively low contribution of the salmon intervention to the RDA for these micronutrients.

This study had several strengths, including its interdisciplinary farm-to-fork design to link sector-representative fish feed formulations to key human health outcomes. Another strength is the intervention amount, which is in line with dietary guidelines, and the relatively long study duration, allowing the assessment of both short and longer-term effects. Study limitations include a relatively small study population of healthy Caucasian subjects, which limits the extrapolation of findings to other relevant groups such as those at risk for cardiovascular disease. Another limitation is that power analysis was only performed for the primary outcome (omega-3 index) and that significant changes in serum 25(OH)D3 and plasma triacylglycerol concentrations, and heart rate, could have been due to chance. However, these changes are in line with those expected based on findings in previous studies.

In conclusion, this study provides robust evidence for the cardiovascular health benefits of consuming farmed salmon. Moreover, our findings show that introduction of more sustainable feeding regimes in the aquaculture sector does not necessarily compromise the health benefits of farmed salmon, as long as two portions/week are consumed.

Acknowledgements We wish to acknowledge Jamie Walton and Paddy Campbell (Biomar), Dougie Hunter and Davy Corrigan (Marine Harvest, now MOWI), and Gordon Bell, Fiona Strachan, James Dick and Douglas Tocher (Stirling University) for their help with the design and preparation of fish feeds, and for the salmon production study. We also wish to acknowledge Kirsty Rolland for her help with the analysis of food diaries.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Sharon Wood, David Brenner, Sabina Bashir, William Fraser and Graham Horgan. The first draft of the manuscript was written by Baukje de Roos and Alan Sneddon, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This research was supported by the Scottish Government’s Rural and Environment Science and Analytical Services Division (RESAS).

Compliance with ethical standards

Conflict of interest None of the authors reported a conflict of interest.

Ethical approval The study was approved by the Ethics Committee of the Rowett Institute, University of Aberdeen.

Consent to participate All subjects provided informed consent prior to starting the study.

Consent for publication All authors whose names appear on the submission consent to this version of the manuscript to be published.

Availability of data and material Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.

Code availability (software application or custom code) N/A.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Joint FAO/WHO expert consultation on the risks and benefits of fish consumption (2010) Rome, FAO/WHO. FAO Fisheries and Aquaculture Report No. 978
2. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Al-Abdulghafoor FK, Summerbell CD, Worthington HV et al (2018) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 7(7):CD003177
3. Xin P, Qin B, Song Y, Nakamura Y, Kurth T, Yaemsiri S, Djousse L, He K (2012) Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies. Eur J Clin Nutr 66:1199–1207
4. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D (2012) Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 15:725–737
5. Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Crowston S, Ward H, Ward H, Johnson L, Crowe F, Hu FB, Franco OH (2012) Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ 345:e6698
6. Food and Agriculture Organization of the United Nations (2018) The State of World Fisheries and Aquaculture. Contributing to Food Security and Nutrition for All. Rome. https://www.fao.org/state-of-fisheries-aquaculture
7. World Bank (2013) Fish to 2030: prospects for fisheries and aquaculture. World Bank Report no. 83177, World Bank, Washington, DC
8. Naylor RL, Hardy RW, Bureau DP, Chiu A, Elliott M, Farrell AP, Forster I, Gatlin DM, Goldburg RJ, Hua K, Nichols PD (2009) Feeding aquaculture in an era of finite resources. Proc Natl Acad Sci USA 106:15103–15110
9. Bostock J, McAndrew B, Richards R, Jauncey K, Telfer T, Lorenzen K, Little D, Ross L, Handisyde N, Gatward I et al (2010) Aquaculture: global status and trends. Philos Trans R Soc Lond B Biol Sci 365:2897–2912
10. Sprague M, Dick JR, Tocher DR (2016) Impact of sustainable feeds on omega-3-long chain fatty acid levels in farmed Atlantic salmon, 2006–2015. Sci Rep 6:21892
11. de Roos B, Sneddon AA, Sprague M, Horgan GW, Brouwer IA (2017) The potential impact of compositional changes in farmed fish on its health-giving properties: is it time to reconsider current dietary recommendations? Public Health Nutr 20:2042–2049
12. Anderson S (2004) Soxtec: Its Principles and Applications. In: Luthria DL (ed) Oil Extraction and Analysis: Critical Issues and Competitive Studies. American Oil Chemists’ Society, Urbana, pp 11–24
13. Food and Agriculture Organisation of the United Nations (2003) Methods of food analysis. Food energy—methods of analysis and conversion factors, Food and Agriculture Organisation of the United Nations, Chapter 2, pp 7–17
14. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
15. de Roos B, Duivenvoorden I, Rucklidge G, Reid M, Ross K, Lamers RJAN, Voshol PJ, Havekes LM, Teusink B (2005) Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data. FASEB J 19:1–26. https://doi.org/10.1096/fj.04-2974fj
16. Denholm SJ, Sneddon AA, McNeilly TN, Bashir S, Mitchell MC, Wall E (2019) Phenotypic and genetic analysis of milk and serum element concentrations in dairy cows. J Dairy Sci 102:11180–11192
17. Harris WS, von Schacky C (2004) The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 39:212–220
18. Harris WS, Pottala JV, Sands SA, Jones PG (2007) Comparison of the effects of fish and fish-oil capsules on the N 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr 86:1621–1628
19. McCance RA, Widdowson EM (2002) McCance and Widdowson’s the composition of foods, 6th edn. Royal Society of Chemistry, Cambridge
20. Nauck M, Warnick GR, Rifai N (2002) Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 48:236–254
21. Claus A (1957) Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 17:237–246
22. Owens DJ, Webber D, Impye SG, Tang J, Donovan TF, Fraser WD, Morton JP, Close GL (2014) Vitamin D supplementation does not improve human skeletal muscle contractile properties in insufficient young males. Eur J Appl Physiol 114:1309–1320
23. Snellman G, Mellhus H, Gedeborg R, Byberg L, Berglund L, Wernoth L, Michaésson K (2010) Determining vitamin D status: a comparison between commercially available assays. PLoS ONE 5:e11555
24. Walker RE, Jackson KH, Tintle NL, Shearer GC, Bernasconi A, Masson S, Latini R, Heydari B, Kwong RY, Flock M et al (2019) Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am J Clin Nutr 110:1034–1040
25. Seierstad SL, Seljeflot I, Johansen O, Hansen R, Haugen M, Rosenlund G, Frayland L, Arnesen H (2005) Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis. Eur J Clin Invest 35:52–59
26. Hallund J, Madsen BO, Bügel SH, Jacobsen C, Jakobsen J, Kranup H, Holm J, Nielsen HH, Lauritzen L (2010) The effect of farmed trout on cardiovascular risk markers in healthy men. Br J Nutr 104:1528–1536
27. Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, Young S, Wang L, Jebb SA, Calder PC (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 96:748–758
28. Harris WS, Del Gobbo L, Tintle NL (2017) The omega-3 index and relative risk for coronary heart disease mortality: estimation from 10 cohort studies. Atherosclerosis 262:51–54
29. Harris WS, Tintle NL, Etherton MR, Vasan RS (2018) ErythrocYTE long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: the Framingham Heart Study. J Clin Lipidol 12:718–727
30. Hagen IV, Helland A, Brattie M, Brokstad KA, Rosenlund G, Sweier L, Mellgren G, Gudbrandsen OA (2016) High intake of fatty fish, but not of lean fish, affects serum concentrations of TAG and HDL-cholesterol in healthy, normal-weight adults: a randomised trial. Br J Nutr 116:648–657
31. Aalldand EK, Lavigne C, Graff JE, Eng Ø, Paquette M, Holte A, Mellgren G, Jacques H, Lieset B (2015) Lean-seafood intake reduces cardiovascular lipid risk factors in healthy subjects: results from a randomized controlled trial with a crossover design. Am J Clin Nutr 102:582–592
32. Hidayat K, Yang J, Zhang Z, Chen GC, Qin LQ, Eggersdorfer M, Zhang W (2018) Effect of omega-3 long-chain polysaturated fatty acid supplementation on heart rate: a meta-analysis of randomized controlled trials. Eur J Clin Nutr 72:805–817
33. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112:1945–1952
34. Lu Z, Chen TC, Zhang A, Persons KS, Kohn N, Berkowitz R, Artiniornello S, Holick MF (2007) An evaluation of the vitamin D3 content in fish: is the vitamin D content adequate to satisfy the dietary requirement for vitamin D? J Steroid Biochem Mol Biol 103:642–644
35. Lehmann U, Rosenfeldh Gjessing H, Hirche F, Mueller-Belecke A, Gudbrandsen OA, Ueland PM, Mellgren G, Lauritzen L, Lindqvist H, Hansen AL et al (2015) Efficacy of fish intake on vitamin D status: a meta-analysis of randomized controlled trials. Am J Clin Nutr 102:837–847
36. Brader L, Reijnmark L, Carlborg C, Schwab U, Kolehmainen M, Rosqvist F, Cloetens L, Landin-Olsson M, Gunnarsdottir I, Poullanen KS et al (2014) Effects of a healthy Nordic diet on plasma 25-hydroxyvitamin D concentration in subjects with metabolic syndrome: a randomized, [corrected] controlled trial (SYSDIET). Eur J Nutr 53:1123–1134
37. Sargent JR, Tocher DR, Bell JG (2002) The lipids. In: Halver JE, McCauley DJ, Smith M, Vaitla B, Zeller D, Myers SS (2016) Fishes of the North-east Atlantic: global status and trends. Philos Trans R Soc Lond B Biol Sci 463:542–554
38. Golden CD, Allison EH, Cheung WW, Dey MM, Halpern BS, McCauley DJ, Smith M, Vaitla B, Zeller D, Myers SS (2016) Nutrition: fall in fish catch threatens human health. Nature 534:317–320
39. Hicks CC, Cohen PJ, Graham NAJ, Nash KL, Allison EH, D’Lima C, Mills DJ, Roscher M, Thilsted SH, Thorne-Lyman AL, MacNeil MA (2019) Harnessing global fisheries to tackle micronutrient deficiencies. Nature 574:95–98
40. Bogard JR, Farook S, Marks GC, Waid J, Belton B, Ali M, Toufigue K, Mamun A, Thilsted SH (2017) Higher fish but lower micronutrient intakes: temporal changes in fish consumption from capture fisheries and aquaculture in Bangladesh. PLoS ONE 12(4):e0175098

41. Betancor MB, Dam TM, Walton J, Morken T, Campbell PJ, Tocher DR (2016) Modulation of selenium tissue distribution and selenoprotein expression in Atlantic salmon (Salmo salar L.) fed diets with graded levels of plant ingredients. Br J Nutr 115:1325–1338
**Supplemental Table 1a. Fish feed composition**

| Feed pellet size | 3mm | 4.5mm | 6.5mm | 9mm | 12mm |
|------------------|-----|-------|-------|-----|------|
| Salmon group     | FO  | RO    | FO    | RO  | FO   | RO   | FO   | RO   | FO   | RO   |
| Fish meal        | 40.8| 40.8  | 42.5  | 42.5| 35.7 | 35.7 | 21.0 | 21.0 | 24.5 | 24.5 |
| Soya cake        | 3.8 | 3.8   | 4.5   | 4.5 | 4.5  | 4.5  | 6.0  | 6.0  | 6.0  | 6.0  |
| Wheat gluten     | 2.5 | 2.5   | -     | -   | -    | -    | 7.0  | 7.0  | 8.0  | 8.0  |
| Sunflower cake   | 11.7| 11.7  | 11.5  | 11.5| 13.0 | 13.0 | 13.0 | 13.0 | 10.4 | 10.4 |
| Corn gluten      | 7.7 | 7.7   | 5.3   | 5.3 | 8.0  | 8.0  | 15.0 | 15.0 | 10.0 | 10.0 |
| Fava beans       | 13.0| 13.0  | 14.5  | 14.5| 13.0 | 13.0 | 6.5  | 6.5  | 6.5  | 6.5  |
| SH fish oil      | 18.9| 8.9   | 20.1  | 9.1 | 24.1 | 11.1 | 8.5  | 2.5  | 8.2  | 2.1  |
| Rapeseed oil     | -   | 10.0  | -     | 11.0| -    | 13.0 | 9.5  | 15.7 | 11.0 | 17.8 |
| Palm olein       | -   | -     | -     | -   | -    | -    | 2.6  | 8.5  | 4.0  | 9.8  |
| Standard fish oil| -   | -     | -     | -   | -    | -    | 7.5  | 1.4  | 8.5  | 2.0  |
| Supplements      | 2.7 | 2.7   | 2.7   | 2.7 | 2.7  | 2.7  | 4.8  | 4.8  | 4.3  | 4.3  |

*FO: fish oil-fed salmon; RO: rapeseed oil-fed salmon; SH fish oil: Southern Hemisphere fish oil.*
Supplemental Table 1b. Feeding schedule

| Diet type | Dates fed                      | Feeding period |
|-----------|--------------------------------|----------------|
| 3 mm      | 04 May 2012 – 14 Jun 2012 (6 wk)| 6 wk           |
| 4.5 mm    | 15 Jun 2012 – 23 Aug 2012 (10 wk)| 10 wk         |
| 6 mm      | 24 Aug 2012 – 10 Oct 2012 (7 wk)| 7 wk           |
| 9 mm      | 11 Oct 2012 – 15 Oct 2012 (1 wk)| 1 wk           |
| 6 mm      | 16 Oct 2012 – 11 Nov 2012 (3.5 wk)| 3.5 wk       |
| 12 mm     | 12 Nov 2012 – 5 Dec 2012 (3.5 wk)| 3.5 wk       |
| 9 mm + 12 mm | 6 Dec 2012 – 18 Dec 2012 (2 wk) | 2 wk          |
| 4.5 mm + 12 mm | 19 Dec 2012 – 07 Jan 2013 (2.5 wk) | 2.5 wk       |
**Supplemental Table 2.** Salmon length and weight during the fish feeding period

|                | FO salmon | RO salmon | p-value |
|----------------|-----------|-----------|---------|
| **Baseline (11 May 2012)** |           |           |         |
| Weight (g) (n=100) | 102.0 ± 2.2 | 95.1 ± 2.4 | 0.037   |
| Length (cm) (n=25)  | 21.9 ± 0.3  | 20.5 ± 1.0 | 0.182   |
| **Midpoint (27 September 2012)** |           |           |         |
| Weight (g) (n=100) | 1.2 ± 0.0   | 1.2 ± 0.0  | 0.128   |
| Length (cm) (n=50)  | 43.6 ± 0.4  | 45.2 ± 0.4 | 0.004   |
| **Final (7 January 2013)**   |           |           |         |
| Weight (g) (n=25)  | 2.4 ± 0.1   | 2.5 ± 0.1  | 0.457   |
| Length (cm) (n=25)  | 56.4 ± 0.6  | 56.8 ± 0.9 | 0.723   |
Supplemental Figure 1. Effects of storage on the fatty acid composition of the fish-oil (FO) and rapeseed oil (RO)-fed salmon. Figures indicate saturated fatty acids (SAT), monounsaturated fatty acids (MUFA), n-6 polyunsaturated fatty acids (n-6 PUFA) and n-3 polyunsaturated fatty acids (n-3 PUFA) as percentage of total fatty acids at harvest (January 2013) and after 3, 6, 9 and 12 months of storage at -80°C.
Supplemental Figure 2. Relationship between plasma inflammatory markers at baseline and responses in O3I and plasma triacylglycerols